Integra LifeSciences Holdings Corporation announced on October 9, 2026, that it has priced $450,000,000 in aggregate principal amount of senior secured notes due 2033. The notes carry a coupon rate of 9.500% and are classified as general senior secured obligations of the company. These obligations are guaranteed by the company's wholly-owned domestic subsidiaries that serve as guarantors under its existing senior secured credit facilities.
The notes are being offered in a private placement pursuant to Rule 144A of the Securities Act and to certain non-U.S. persons outside the United States in compliance with Regulation S. The transaction is part of a broader refinancing plan. The company intends to use the net proceeds from the sale of the notes, combined with borrowings from a new credit facility, to refinance its existing credit facilities and cover associated fees and expenses.
The sale of the notes is expected to close on or about October 19, 2026, subject to customary closing conditions. The notes have not been registered under the Securities Act of 1933 and will be offered only to qualified institutional buyers and specified non-U.S. persons.
